Crizotinib showed clinical benefit for NSCLC patients with ALK rearrangement beyond cytotoxic chemotherapy in the PROFILE 1007 trial and PROFILE 1014 trial, and has been approved and used in clinical practice [9,10]. This evidence concerns the gene ALK and non-small cell lung carcinoma.